New York, NY (PRWEB) October 16, 2012
New York, NY – (PRWEB) October 16, 2012 – Ceres Ventures, Inc. (OTCQB: CEVE) (the “Company”) a development stage company currently developing novel cost-effective water purification and treatment technologies to meet the water challenges and business opportunities arising in key sectors of the global economy, announced today that as part of the Company’s ongoing efforts to advance the commercialization of its proprietary BluFlow™ Treatment System, the Company is currently negotiating a Memorandum of Understanding (“MOU”) with Brown and Caldwell (“BC”), a major U.S. Professional Environmental and Engineering & Consulting firm servicing Fortune 100 clients and municipalities throughout the U.S. BC would function as the engineering, procurement, and construction, and operations & maintenance partner for one or more sectors of the U.S. water, groundwater, and wastewater applications of the BluFlow™ Treatment Systems within the United States.
This announcement comes following the Company’s successful completion of a laboratory scale treatability study on behalf of BC, which the Company conducted in anticipation of upcoming field tests of the Company’s BluFlow™ Treatment system at sites maintained or operated by clients of, and designated by, BC.
“We were extremely pleased with the results of the treatability study Ceres Ventures conducted on our behalf for a problematic emerging contaminant and believe that the BluFlow™ Treatment System has the opportunity to become a cost-effective alternative to conventional treatment systems in the water remediation and purification sector. We hope that, with our entrance into a finalized Memorandum of Understanding, we can continue to grow a mutually beneficial relationship as Ceres Ventures continues their commercialization efforts,” said Jeffrey L. Pintenich, P.E., BCEE, CHMM, Vice President and Technology Director of Brown and Caldwell.
The laboratory scale treatability study proved the effectiveness of the Company’s BluFlow™ Treatment System’s ability to treat groundwater contaminated with 1,4-Dioxane and 1,1-Dichloroethene. The first compound, 1,4-dioxane, is on the United States Environmental Protection Agency’s‘Contaminant Candidate List or CCL to be considered for regulation under the federal Safe Drinking Water Act (SDWA). 1,4-Dioxane was described in the U.S. Department of Health and Human Services 12th Report on Carcinogens (June 10, 2011) "as reasonably anticipated to be a human carcinogen" and identified as a contaminant in water at sites throughout the United States.1,1-Dichloroethene is already regulated nationally under the SDWA..
“We are committed to growing into a significant participant in the potable water and wastewater industry encompasing many specialized markets including, but not limited to, groundwater remediation, management of industrial process plant effluents, oil and gas exploration effluent operations, and landfill leachates. Developing the appropriate channel and engineering partnerships is going to be a key to our long term growth and profitability. BC is an ideal engineering, procurement, and construction and maintenance partner for the U.S. water and wastewater applications of our BluFlow™ Treatment Systems. As one of the largest engineering consulting firms focused solely on the U.S. environmental sector, Brown and Caldwell has a strong reputation in the industry for providing their clients with innovative solutions that build value and relationships that last,” explained Meetesh Patel, the Company’s Chief Executive Officer.
The BluFlow™ Treatment System is unique because it is a first-of-kind single integrated system that simultaneously permits the removal of target chemicals/pollutants and, if desired, can further purify the water to drinking quality versus legal discharge standards. If required the final purification step can operate in ways that minimize the reject stream.
The Company’s proprietary technologies, include:
- BluFlow™ Pure, a nanoparticle-based purifying agent that can be customized so that it can target and remove specific contaminants or conversely capture desirable elements or compounds that are in process effluents. Unlike conventional wastewater treatment technologies that simply reduce the concentration of contaminants in water, the specialized BluFlow™ Pure used by the BluFlow™ Treatment System allows the system to target and remove specific elements or compounds from contaminated water; and
- BluFlow™ Advanced Ultrafiltration Technology, a fully automated process for recovering water from impure streams that achieves usable water recovery of 85-95%, a significant increase over conventional technologies such as reverse osmosis or multistage reverse osmosis with chemical treatment that only have usable water recoveries of 50-60%.
Water is essential for life and drives economic progress, but the earth’s freshwater resources are being depleted at an alarming rate. As a result, public and private entities are searching for new ways to treat wastewater for potential reuse and the water treatment industry is currently estimated at $500 billion worldwide annually. This is estimated to increase to $1 trillion by 2020. Component technologies that address water purification to different degrees, such as the BluFlow™ Treatment System, can account for about 10% of that market.
About Ceres Ventures, Inc.
Ceres Ventures, Inc., together with its wholly owned subsidiaries is a developer of next generation clean technologies for the remediation and purification of water, air, and soil. Over time, the Company seeks to actively deliver environmental remediation systems and services to address the water, air and soil markets. Based on the essential nature of water, the Company’s initial focus is on the water market.
The Company’s patent-pending BluFlow™ Treatment System is a first-of-its-kind single integrated treatment solution that simultaneously removes specific target chemicals whether they be pollutants or valuable elements and compounds and does so at very high efficiencies. If drinking water purity is required versus a legal discharge objective then the systems, with unique recirculation treatment technology, can be designed to achieve this goal with unparalled efficiency and economics.
For additional information, please visit: http://www.ceresventures.com or contact 1-800-611-3388.
To receive future press releases via email, please visit: http://www.ceresventures.com/contact
To view the full HTML text of this release, please visit: http://www.ceresventures.com/ceres-ventures-brown-and-caldwell/
About Brown and Caldwell
Since 1947, Brown and Caldwell has delivered innovative, enduring environmental solutions for private industry, municipalities, and government agencies throughout the United States. An employee-owned company, Brown and Caldwell is relentlessly focused on client needs and brings decades of engineering and scientific experience to every project. Our experience includes traditional and innovative chemical, biological, and physical treatment and remediation technologies, as well as a strong track record of working with regulators to implement state-of-the-art, science-based approaches. Our collaborative culture promotes close communication and consensus-building between our engineers and scientists, clients, regulators, and other stakeholders. We develop cost-effective, sustainable solutions for a range of services that include the planning, design, implementation, and operation of small- and large-scale remediation, wastewater, and water systems. Through 45 offices and 1,500 employees, our realistic technical and risk-based approaches leverage local regulatory knowledge and relationships while meeting our clients’ long-term goals—a formula for success that has been proven to save significant time and expense. http://www.brownandcaldwell.com
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although Ceres Ventures, Inc. (the “Company” or Ceres Ventures”) believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words “may,” “will,” “should,” “could,” “expect,” “anticipate,” “estimate,” “believe,” “intend,” or “project” or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. There can be no assurance that further research and development will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that Ceres Ventures will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-Q and Form 10-K filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.